Relatively mild symptoms after chronic intoxication with a double dose
encorafenib: a case report
Abstract
Introduction: Encorafenib (BraftoviTM) is indicated for the treatment of
adult patients with unresectable or metastatic melanoma with a BRAF V600
mutation, in combination with binimetinib (Mektovi ®). According to the
product label of encorafenib, there are no specific treatment
recommendations in case of an overdose. Case presentation: We report on
a 63 year old man who ingested a double dose (900 mg) of encorafenib for
16 days. He developed overall minor chronic intoxication symptoms such
as upset stomach, bloating, occasional vomiting and muscle pain. Based
on the most occurring adverse events of encorafenib, liver values,
kidney function parameters and QTc interval were measured. Kidney
function parameters were normal, whereas liver values were slightly
increased and QTc slightly prolonged. The plasma concentration 3 hours
after the last dose was 2110 ng/mL. Conclusion: We describe the course
of a case with a chronic toxicity during 16 days of double dose of
encorafenib as well as the followed approach, which could be taken into
account when treating a patient with encorafenib intoxication.